/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.
WIRE SERVICES/
WINNIPEG, April 10, 2018 /CNW/ - DELTA 9 CANNABIS INC.
(TSXV: NINE) ("Delta 9" or the "Company") has entered into a
non-binding letter of intent (the "Letter of Intent") to become a
preferred supplier of medical cannabis to Pharmasave.
Pharmasave is a member owned and governed cooperative of more
than 650 independent community pharmacies across Canada. Pharmasave believes that pharmacists,
as medication management experts, play an important role in helping
to improve patient care. For more than a year, Pharmasave has been
providing education and resources on medical cannabis to help
Pharmasave pharmacists understand more about the current
regulations and learn more about the possible uses, benefits and
risks of medical cannabis. Pharmacists can provide advice on
potential drug-to-drug interactions and the therapeutic value of
treatment options to patients and allied health professionals to
help them make educated and informed decisions about products and
monitoring.
Following execution of the Letter of Intent, the two companies
are jointly working to conclude definitive agreements for supply
and distribution of Delta 9's medical cannabis through Pharmasave
pharmacists, pending changes to Canadian legislation that would
allow such distribution.
Delta 9 CEO John Arbuthnot says
the agreement is part of Delta 9's ongoing commitment to supplying
patients with the medical products they need in a timely and
reliable manner.
"There has been a lot of discussion about the upcoming
legalization of recreational cannabis, but we at Delta 9 remain
committed to providing our medical cannabis patients with the
products they require," Arbuthnot said. "Pharmasave and its member
stores provide the expertise and professionalism this industry
needs to ensure patients are receiving the correct products, and
good advice on how to use these products for their particular
condition or symptoms."
"We believe this agreement with Pharmasave is a critical part of
professionalizing the medical cannabis industry, and we are
dedicated to providing the best products and service possible to
our patients."
The parties are currently working on agreement terms to ensure
compliance with the Access to Cannabis for Medical Purposes
Regulations (Canada) and all other
applicable laws and regulations.
About Delta 9 Cannabis Inc.
Delta 9's wholly-owned
subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of
medical marijuana pursuant to the ACMPR and operates an 80,000
square foot production facility in Winnipeg, Manitoba, Canada. Delta 9's shares
trade on the TSX Venture Exchange under the symbol "NINE".
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking
statements, which reflect the expectations of management regarding
the Company's future business plans and other matters.
Forward-looking statements consist of statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to: (i) the execution of definitive supply and distribution
agreements between Pharmasave and Delta 9; and (ii) anticipated
changes to cannabis legislation in Canada. Such statements are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
statements, including that Delta 9's currently contemplated
expansion and development plans may cease or otherwise change,
Delta 9's production of cannabis may be lower than expected, Delta
9 may not obtain the required approvals from Health Canada, demand
for Delta 9's products may be lower than anticipated, Delta 9's
cost to produce its grow pods may be higher than expected and all
other risk factors set forth in the filing statement of Delta 9
dated October 25, 2017 which has been
filed on SEDAR. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them.
Readers are urged to consider these factors carefully in evaluating
the forward-looking statements contained in this news release and
are cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by these
cautionary statements. These forward-looking statements are made as
of the date hereof and the Company disclaims any intent or
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or results or
otherwise, except as required by applicable securities
laws.
SOURCE Delta 9 Cannabis Inc.